Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Histotripsy for Renal Cell Carcinoma (HRCC)

11. November 2026 aktualisiert von: Matthew Kin Liang Chiu, The University of Hong Kong

Histotripsy for Renal Cell Carcinoma: a Pilot Study for a Novel Focused Therapy With an Unmet Need

The project will be a pilot study in localised or metastatic renal cell carcinoma, assessing safety, local control, and exploratory immune endpoints. Outcomes from this work will inform rational combinations with targeted agents and immune checkpoint blockade and may define a new, image-guided, non-invasive modality for renal cell carcinoma. If successful, histotripsy could become a new non-thermal, local therapy for renal cell carcinoma with dual benefits of debulking and immune activation achieving strong clinical and scientific impact.

Studienübersicht

Status

Rekrutierung

Detaillierte Beschreibung

Study Design and Methodology

This study will enrol 15 patients with localised or metastatic renal cell carcinoma. Patients will be identified from clinic, and undergo a comprehensive evaluation, including imaging studies and laboratory tests, to confirm the diagnosis and assess their eligibility for histotripsy.

Procedure

Histotripsy will be performed by dedicated team of oncologist, urologist and radiologist who have undergone accredited training on Histotripsy aiming to achieve the best clinical outcomes and ensure patient safety. Patients are typically placed under general anaesthesia (GA) or monitored anaesthesia care (MAC) with real-time monitoring. The component of the Histotripsy machine that generates sound waves is positioned within a soft, flexible membrane filled with specially treated water, which rests on the patient's abdomen and facilitates the transmission of sound waves to the targeted tissue. The procedure will be delivered in a single session or multiple sessions by ultrasound, depending on the size and location of tumours.

Assessment

Patients will be invited to complete a questionnaire for pain score assessment before and after histotripsy.

Blood samples will be collected for clinical evaluation and laboratory tests at baseline, followed by 1-day, 30-day, 60-day, and 90-day after histotripsy, aligned with existing feasibility and trial schedules. Blood tests and cellular analysis such as complete blood profile, liver and renal function tests, tumour markers, immune markers and biomarkers etc. will be performed each time. Patients will be asked for consent for 15ml blood collection for the cellular analysis.

Serial post-histotripsy imaging (CT/MRI) will also be arranged. Imaging within 36-hour after histotripsy will be proceeded to confirm the ablation zone and assess complications. Post-procedure imaging at 1-, 3-, and 6-month will help to capture the sustainability of treatment effect, then per standard of care thereafter.

Admission and follow-up

Similar to other minimal invasive treatments, patients will be admitted one day prior, or on the day of procedure. After the procedure of histotripsy, patients may experience some discomfort in the treated area, but patients can often return to normal activities quickly. They could be discharged in few hours, or the next day after procedure depending on clinical conditions.

After discharge, follow-up consultations and assessments such as regular imaging and blood tests will be arranged accordingly.

Potential risk and discomfort

Blood drawn for laboratory tests can cause bruising at or near the site where the needle enters the vein and thus increase the risk of infection. Risks related to imaging scans will be explained prior to the procedures by the related doctors or medical professionals.

Procedure risk related to Histotripsy includes skin erythema or superficial burn injury, infection, bleeding, renal dysfunction, and abdominal wall injury or burn. Adverse post treatment event includes bleeding, infection, damage to surrounding structures etc. The medical team will monitor closely and response promptly.

Short-term effects

  • Mild pain or soreness that usually responds to oral pain medication
  • Low-grade fever and flu-like symptoms that typically resolve within 48 hours
  • Temporary skin redness at the treatment site
  • Mild abdominal discomfort
  • Temporary changes in renal function tests
  • Possible nausea or fatigue
  • Transient haematuria

Potential serious complications

  • Temporary decrease in kidney function
  • Potential damage to surrounding organs (liver, lung, bowel, or stomach)
  • Severe pain
  • Need for extended hospital stay or additional treatment for serious complications
  • Skin ulcer / necrosis requiring interventions
  • Vascular thrombosis / dissection

Long-term complications

• Currently, there is no known long-term side effects from Histotripsy treatment. Ongoing research aims to evaluate the long-term outcomes.

In the event of complications arising from the study treatment, patients will be treated accordingly or referred for standard treatment and care.

Statistical analysis

Analysis will be performed for the 15 participants recruited, with basic demography (age, sex, medical history etc.), clinical evaluation, laboratory tests, imaging, treatment outcome with associated complication.

DATA AND BIOLOGICAL SAMPLES HANDLING

Patients will be invited to register on the Histotripsy (HistoSonics○R) Registry in Gleneagles Hospital Hong Kong for data collection. Collected personal and study data will be anonymised and stored in a password protected, encrypted database with the principal investigator and delegated staff in the long run. The principal investigator will be responsible for the safekeeping. Only investigators and delegated staff can have right to gain access to the data. All collected data and biological samples will be stored permanently for future review in histotripsy related research. Unused biological samples will be destroyed and discarded upon request, however, the results will remain a part of the overall research data if part of the sample has been proceeded.

Consent

Written voluntary consents will be obtained after full explanation of the study to patients before agreement of the histotripsy procedure.

Conflicts of interests

All investigators and funding bodies have no financial interests in the study.

Research ethics

The study will be performed in accordance with ethical principles that have their origin in the Declaration of Helsinki and are consistent with ICH/Good Clinical Practice, and applicable regulatory requirements Patient data protection.

Studientyp

Interventionell

Einschreibung (Geschätzt)

15

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

  • Name: Professor Matthew Kin-liang CHIU, PhD
  • Telefonnummer: +852 22554352
  • E-Mail: mklc2@hku.hk

Studienorte

      • Hong Kong, Hongkong
        • Rekrutierung
        • Gleneagles Hospital Hong Kong
        • Kontakt:
          • Professor Matthew Kin-liang CHIU, PhD
          • Telefonnummer: +852 22554352
          • E-Mail: mklc2@hku.hk
        • Unterermittler:
          • Wing Hang Vince Lau, MBBS, FHKCR, FHKAM
        • Unterermittler:
          • Chi-Yan Albert Chan, MBBS, MS, FRCSEd, FCSHK, FHKAM
        • Unterermittler:
          • Justin Christopher Ng, MBBChBAO, LMCHK, MMED, FRCR
        • Unterermittler:
          • Pei Wayne Lam, MBBS, LMCHK, FRCSed, FCSHK
        • Unterermittler:
          • Cho Wing Bryan Li, MBBS, MRCP, FHKCP, FHKAM
        • Unterermittler:
          • Shung Lai John Leung, MBBS, FRCSEd, FCSHK, FHKAM
        • Unterermittler:
          • Lok Hei Clarence Leung, MBChB, FRCSEd, FCSHK, FHKAM
        • Unterermittler:
          • Hin Kay John Ngan, MBBS, FHKCS, FHKAM, FRCSE

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Age ≥ 18 years old
  • Fit for general anaesthesia
  • Histologically confirmed renal cell carcinoma; radiological diagnosis acceptable if biopsy is not feasible
  • With or without distant metastases
  • Eastern Cooperative Oncology Group Performance Status (ECOG PS) grade 0-2
  • Tumour visible and targetable by ultrasound with acceptable acoustic windows
  • Adequate hematologic, hepatic, and renal function (eGFR ≥45mL/min, ≤14 days prior to the planned index procedure date).

Exclusion Criteria:

  • Refusal to take part in clinical trial
  • Not fit for general anaesthesia
  • Poor general condition with limited life expectancy
  • Uncontrolled coagulopathy
  • The treatment of the tumour will not allow for an adequate margin as determined by the investigator

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: N / A
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Patients receiving Histotripsy procedure for renal cell cancer using the HistoSonics® Edison System

Patients with be admitted to Gleneages Hospital for histotripsy procedure. Pre-produce anaestetic assessment will occur and patients will be treated under general anasestetic with jet ventilation. Patient will be positioned in the left or right lateral position and a water tank will be placed over the patient's loin area. The histotripsy ultrasound and treatment head will be placed inside the water tank and image-guided histotripsy ablation of the kidney tumor will be performed. The expected length of hospital stay is 1 day after operation. Patient will undergo follow up with regular imaging up to 6 months.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
To assess efficacy
Zeitfenster: 90 days post procedure

Successful treatment percentage at 90 days on MRI/CT post-procedure

90 days post procedure
To assess treatment safety
Zeitfenster: At 30 days

Freedom from index procedure related major complications, defined by Clavien-Dindo Classification Grade 3 or higher

At 30 days

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Zeitfenster
Pain score assessment before and after histotripsy
Zeitfenster: At baseline (after inpatient admission and before histotripsy) and day 2 (before discharge of patient) on a 11-point scale Numeric Pain Rating Scale (NPRS).
At baseline (after inpatient admission and before histotripsy) and day 2 (before discharge of patient) on a 11-point scale Numeric Pain Rating Scale (NPRS).

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

13. Oktober 2026

Primärer Abschluss (Geschätzt)

30. Oktober 2028

Studienabschluss (Geschätzt)

30. Oktober 2029

Studienanmeldedaten

Zuerst eingereicht

17. September 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

11. November 2026

Zuerst gepostet (Tatsächlich)

17. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

17. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

11. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Ja

Produkt, das in den USA hergestellt und aus den USA exportiert wird

Ja

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren